



07/25/06

## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to:

Mail Stop ISSUE FEE  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 or Fax (571)-273-2885

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

7590 05/01/2006

Jane T. Gunnison  
 Fish & Neave  
 1251 Avenue of the Americas  
 New York, NY 10020-1105

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or power of attorney, must have CERTIFICATE OF EXPRESS MAIL

I hereby certify that this Issue Fee Transmittal is being deposited with the United States Postal Service by Express Mail No. EV593934531 US addressed to Mail Stop Issue Fee address above on the date indicated below.

the United  
n envelope  
facsimile  
JW.

Brenda T. Kowalcuk

(Depositor's name)

(Signature)

(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/742,993	12/20/2000	Mark Pines	C07/8	8795

TITLE OF INVENTION: QUINAZOLINONE CONTAINING PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF NEOVASCULARIZATION AND FOR TREATING MALIGNANCIES

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$700	\$0	\$700	08/01/2006
EXAMINER	ART UNIT	CLASS-SUBCLASS			
LEWIS, AMY A	1614	514-259000			

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

"Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

Sullivan & Worcester LLP

2 \_\_\_\_\_

3 \_\_\_\_\_

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(1) **(A) NAME OF ASSIGNEE** Hadasit Medical Research Services and Development Company Ltd. - Jérusalem, Israel  
**(B) RESIDENCE: (CITY and STATE OR COUNTRY)**  
 and Agricultural Research Organization Ministry of Agriculture - Bet Dagan, Israel

(2) Please check the appropriate assignee category or categories (will not be printed on the patent):  Individual  Corporation or other private group entity  Government

4a. The following fee(s) are enclosed:

Issue Fee  
 Publication Fee (No small entity discount permitted)  
 Advance Order - # of Copies \_\_\_\_\_

4b. Payment of Fee(s):

A check in the amount of the fee(s) is enclosed.  
 Payment by credit card. Form PTO-2038 is attached.  
 The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number \_\_\_\_\_ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature Diana M. Steel

Typed or printed name Diana M. Steel, D. Phil.

Date July 25, 2006Registration No. 43,153

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

07/27/2006 MAHMED2 00000057 09742993

700.00 DP

01 FC:2501



EXPRESS MAIL MAILING LABEL NO.: EV593934531US

PATENT

Attorney Docket No.: COL-001  
(Previous Docket No. C07/8)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Pines *et al.* GROUP NUMBER: 1614  
SERIAL NUMBER: 09/742,993 CONFIRMATION NUMBER: 8795  
FILING DATE: December 20, 2000 EXAMINER: Amy A. Lewis  
TITLE: QUINAZOLINONE CONTAINING PHARMACEUTICAL COMPOSITIONS  
FOR PREVENTION OF NEOVASCULARIZATION AND FOR TREATING  
MALIGNANCIES

Mail Stop: Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**TRANSMITTAL OF ISSUE FEE**

In response to the NOTICE OF ALLOWANCE AND FEE(S) DUE mailed on May 1, 2006,  
attached please find:

- (a) Issue Fee Transmittal (Form PTOL-85B); and
- (b) a check in the amount of \$700.00 for payment of Issue Fee.

Please charge Deposit Account No. 50-3211 for any additional fees that may be due for this  
application.

Respectfully submitted,

  
Diana M. Steel, D. Phil.  
Attorney for Applicants  
Sullivan & Worcester LLP  
One Post Office Square  
Boston, MA 02109

Date: July 25, 2006  
Reg. No. 43,153  
Tel. No. (617) 338-2952  
Fax No. (617) 338-2880